Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: May 2009

Executive Summary

Top Tier Biotechs, as opposed to Big Pharma, featured as the prominent dealmakers with Celgene standing out thanks to its $540 million license to GlobeImmune's cancer programs. In M&As generics grabbed the attention of Novartis, which paid $1.2bn for Ebewe Pharma; meanwhile Covidien's $470 million takeover of Vnus expands its presence in the vascular market. The $1.2bn in biopharma financing was way up versus last month, but device fund-raising didn't fare as well, dropping 61%.

You may also be interested in...



WHO To Clean Up Data Integrity Failings

The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date. 

Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

Warning Letter Roundup & Recap – 10 December 2019

No device-related warning letters were released by the US FDA the week of 10 December.

Topics

UsernamePublicRestriction

Register

IV003335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel